Key facts
- It has raised $250K; the latest was Seed Round in May 2025.
- Notable investors include SOSV, Endless Frontier Labs, IndieBio, New York Ventures, GS Ventures (Korea) — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Calder Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Calder Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Calder Biosciences
Developer of a vaccine technology designed to improve and save lives by creating safe and effective subunit vaccines against harmful diseases. The company's platform enables the development of conformationally stable immunogens with enhanced antibody responses, improved thermostability, and reduced cold chain requirements, enabling global populations with more accessible and effective vaccines.
- Sector
- Healthcare
- HQ
- Brooklyn, NY, United States
- Founded
- 2018
- Employees
- 8
- Website
- calderbiosciences.com/
- Ownership
- Privately Held (backing)
Calder Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Calder Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Calder Biosciences in its N-PORT filings yet. We sweep new filings monthly.